EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Clinical impact of bacterial heteroresistance

Callum Joyce, Saba Anwar, Charlotte Hind, J Mark Sutton, Chrysi Sergaki

JAC-Antimicrobial Resistance · 30.04.2026 · 8 (3)

DOI: 10.1093/jacamr/dlag075 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift JAC-Antimicrobial Resistance, online erschienen am 22.05.2026. Verfasst von Callum Joyce und 4 weiteren Autor:innen. Beteiligte Einrichtung: Science and Research, Medicines and Healthcare Products Regulatory Agency, South Mimms, Hertfordshire, UK. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: MHRA), UKHSA), Department of Health and Social Care.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bacterial heteroresistance is defined when a seemingly susceptible population of bacteria contains one or more resistant subpopulations. This behaviour has been seen in a variety of bacteria and with many different antibiotics. Heteroresistance is largely unrecognized during clinical diagnosis, because it is hard to accurately test for in a clinical lab using standard antibacterial test methodologies. Overlooking heteroresistance may contribute to inaccurate definitions of antibiotic susceptibility and could lead to poorer patient outcomes, undermining global antimicrobial stewardship. Awareness of the clinical impact of heteroresistance should be better represented in antimicrobial susceptibility test guidance, so clinicians can better spot heteroresistance when present and adjust dosing or treatment plans if necessary. Development of viable clinical tests for heteroresistance should be made a research priority, allowing us to better understand, test and treat heteroresistant bacteria.

Autor:innen und Institutionen

  • Science and Research, Medicines and Healthcare Products Regulatory Agency, South Mimms, Hertfordshire, UK.
  • Antimicrobial Discovery Development and Diagnostics (AD3) Team, Vaccine Development and Evaluation Centre, UK Health Security Agency, Porton Down, Salisbury, Wiltshire SP4 0JG, UK.
  • Institute of Pharmaceutical Science, King's College London, London SE1 1DB, UK.

Förderung

  • MHRA)
  • UKHSA)
  • Department of Health and Social Care
  • National Institute for Health and Care Research

Zitieren

APA

Joyce, C., Anwar, S., Hind, C., Sutton, J. M., & Sergaki, C. (2026). Clinical impact of bacterial heteroresistance. JAC-Antimicrobial Resistance, 8(3). https://doi.org/10.1093/jacamr/dlag075

Vancouver

Joyce C, Anwar S, Hind C, Sutton JM, Sergaki C. Clinical impact of bacterial heteroresistance. JAC-Antimicrobial Resistance. 2026;8(3). doi:10.1093/jacamr/dlag075

BibTeX
@article{Joyce2026,
  author = {Joyce, Callum and Anwar, Saba and Hind, Charlotte and Sutton, J Mark and Sergaki, Chrysi},
  title = {Clinical impact of bacterial heteroresistance},
  journal = {JAC-Antimicrobial Resistance},
  year = {2026},
  volume = {8},
  number = {3},
  doi = {10.1093/jacamr/dlag075}
}
Kostenlos starten →